04/01/2026
AON is at the forefront of bringing bispecific therapy—also known as BiTE therapy—into community oncology practices.
This innovative treatment is designed to help the immune system recognize and attack cancer cells, offering new options for patients with conditions such as multiple myeloma, non-Hodgkin lymphoma, small cell lung cancer, and uveal melanoma.
By expanding access to bispecific therapy in outpatient settings, AON is making cutting-edge cancer care more available, more convenient, and more hopeful for patients and their families.
Learn more in this BiTE video: https://hubs.li/Q049mmGj0